Multi-alleles predict primary non-response to infliximab therapy in Crohn’s disease

BACKGROUND: Infliximab (IFX) is the first-line treatment for patients with Crohn’s disease (CD) and is noted for its relatively high cost. The therapeutic efficacy of IFX has noticeable individual differences. Known single-gene polymorphisms (SNPs) are inadequate for predicting non-response to IFX....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Cai-Bin, Tang, Jian, Wang, Xue-Ding, Lyu, Kun-Sheng, Huang, Min, Gao, Xiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560039/
https://www.ncbi.nlm.nih.gov/pubmed/34733528
http://dx.doi.org/10.1093/gastro/goaa070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560039/
https://www.ncbi.nlm.nih.gov/pubmed/34733528
http://dx.doi.org/10.1093/gastro/goaa070

Ejemplares similares